A Phase 1 Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients with Advanced Solid Tumors

Protocol: 
AAAR1316
Phase: 
I

A Phase 1 Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients with Advanced Solid Tumors

This is a Phase 1 multiple dose, dose escalation trial in patients with
advanced solid tumors who have failed or cannot tolerate standard therapies.
Your study doctor has determined that you have an advanced cancer (solid
tumor). You are invited to take part in this research study. This study
has two parts. In Part 1, the dose escalation portion, the purpose of the
study is to determine the highest dose that can be safely given to subjects
(the Maximum Tolerated Dose [MTD]) or a dose that is considered most
effective to treat your cancer. In Part 2, or expansion portion, the purpose
of the study is to learn more about the safety of AEB1102 in patients with
advanced solid tumors of specific type, to understand the effects of AEB1102
on levels of L-Arginine in blood and, when possible, on tumor tissue and to
study the effects of AEB1102 on tumor growth. Up to 48 subjects with
advanced solid tumors will be joining Part 1 of this study and up to 75
subjects with advanced solid tumors will be joining Part 2 of this study.

Are you Eligible? (Inclusion Criteria)

1. Has an advanced solid tumor, has failed or cannot tolerate standard therapy
for the disease and as such is considered a candidate for Phase 1 treatment.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States